Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
暂无分享，去创建一个
L. Mariani | F. D. De Braud | D. Raggi | A. Necchi | P. Giannatempo | N. Nicolai | L. Piva | D. Biasoni | M. Catanzaro | T. Torelli | S. Stagni | R. Salvioni | A. Gianni | E. Faré | G. Pizzocaro | M. Maffezzini